Andrea Pfeifer, AC Immune CEO

How do you put a pos­i­tive spin on ug­ly da­ta? AC Im­mune gives it a shot in the wake of the lat­est crenezum­ab flop

Re­searchers spent close to a decade look­ing for signs that the failed Alzheimer’s drug crenezum­ab might work in a study that re­strict­ed it­self to a group of fam­i­lies with a rare ge­net­ic mu­ta­tion that left them sus­cep­ti­ble to ear­ly-on­set dis­ease.

It failed. And to­day we’re get­ting a bet­ter look at just how bad the da­ta are — and a biotech’s will­ing­ness to tout it any­way as AC Im­mune takes its turn at the Alzheimer’s As­so­ci­a­tion In­ter­na­tion­al Con­fer­ence.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.